Suscribirse

Safety and effectiveness of CATCH+ as a first-line device for revascularization in the treatment of acute ischemic stroke - 28/09/19

Doi : 10.1016/j.neurad.2019.07.009 
Elena Ernst a, Panagiotis Papanagiotou a, Mary Politi a, Maria Alexandrou a, Andreas Kastrup b, Maria Boutchakova a, Christian Roth a,
a Clinic for Diagnostic and Interventional Neuroradiology, Klinikum Bremen Mitte, Bremen, Germany 
b Clinic for Neurology, Klinikum Bremen Mitte, Bremen, Germany 

Corresponding author at: Clinic for Diagnostic and Interventional Neuroradiology, Klinikum Bremen Mitte, St. Jürgenstr. 1, Bremen, 28205, Germany.Clinic for Diagnostic and Interventional Neuroradiology, Klinikum Bremen MitteSt. Jürgenstr. 1Bremen28205Germany
En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Saturday 28 September 2019
This article has been published in an issue click here to access

Highlights

The aim of the present study was to evaluate the safety and effectiveness of the CE certified CATCH+ stent retriever.
Evaluation of the CATCH+ device in a real-world setting presenting the largest number of clinical patients treated with this device.
The device is safe for usage as a first line device in intracranial thrombectomy.
Similar performance characteristics to the Solitaire FR device with comparable clinical and angiographic results.
Stroke is the most common cause of permanent disability, the second most common cause of dementia, and the fourth most common cause of death in the Western world.

El texto completo de este artículo está disponible en PDF.

Abstract

Purpose

Mechanical thrombectomy devices and stent retrievers have recently been advocated for use as first-line therapy in acute ischemic stroke. Here we evaluate the safety and effectiveness of the CATCH+ stent retriever as a percutaneous thrombectomy device.

Methods

A retrospective analysis was performed on 101 consecutive patients who presented with anterior or posterior intracranial vessel occlusion and were treated with the CATCH+ intracranial system, either alone or in combination with intravenous tissue plasminogen activator, at a single treatment center. The primary outcome measure was successful post-procedural reperfusion as classified by the mTICI score. Secondary endpoints included mortality rate, incidence of adverse events, and functional outcomes evaluated at discharge using the mRS score.

Results

Sixty-nine (68.3%) patients received thrombolysis prior to mechanical thrombectomy. Successful reperfusion (mTICI2b) was achieved in 73.3% of patients at the end of the procedure, and good functional outcomes (mRS2) were observed in 32.7% of patients at discharge. Three patients developed asymptomatic subarachnoid hemorrhage, two developed asymptomatic dissections of the internal carotid artery, and one patient developed a symptomatic intracranial hemorrhage. Seventeen patients died (mortality rate 16.8%).

Conclusions

The CATCH+ device is a safe and effective mechanical thrombectomy device for the first-line treatment of acute ischemic stroke.

El texto completo de este artículo está disponible en PDF.

Keywords : Ischemic stroke, Stent retriever, Mechanical thrombectomy, CATCH+


Esquema


© 2019  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.